logo-loader
Energy
Ophir Energy Plc

Ophir Energy upgraded by Macquarie as Fortuna advances

Macquarie has now upgraded its rating of Ophir to ‘outperform’ from ‘neutral’, as the Fortuna project advances towards an anticipated final investment decision in the first half of 2017.

oil offshore platform
Macquarie is lifting its price target to 95p

Ophir Energy Plc (LON:OPHR) shares have been tipped by Macquarie to rise to 95p, from 74.68p currently, as the Fortuna project advances towards an anticipated final investment decision in the first half of 2017.

Analyst Kate Sloan explains that a recent deal – which saw existing partner Golar LNG establish a new tie-up bringing Schlumberger into the venture - has de-risked Ophir’s participation in the project.

“Ophir will now have an economic interest in both the upstream and midstream components of the project (previously just the upstream),” Sloan said in a note.

“This substantially removes the potential impact of the tariff structure on valuation, and, as such, the attractiveness of the project is now primarily driven by the gas price.

“Now that a financing solution is in place, there is a lower risk of Ophir needing to forward sell the gas into Europe on NBP-linked contracts, in our view.”

The analyst also highlights that Ophir continues to discuss Brent pricing in its announcements, and Macquarie is now factoring in greater influence of oil prices into the broker’s model.

“At our oil price assumptions (US$74 long term), Fortuna LNG is an attractive project, generating a 22% IRR. At US$60 long term, which appears to be the assumption under which Ophir is running its forecasts, we estimate a project IRR of 19.5%, which is still attractive,” she added.

Macquarie has now upgraded its rating of Ophir to ‘outperform’ from ‘neutral’.

Quick facts: Ophir Energy Plc

Price: £0.00

Market: LSE
Market Cap: £0.00
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CB2 Insights licenses electronic data capture software to UK...

CB2 Insights (CSE:CBII-OTCQB: CBIIF) CEO Prad Sekar joined Steve Darling from Proactive Vancouver to discuss the company doing a deal with MYACCESS Clinics. This will allow CB2’s software to capture comprehensive data sets related to patient health and treatment histories and manage ongoing...

1 hour, 2 minutes ago

2 min read